Stonegate Capital Partners has updated its coverage on Burcon Nutrascience Corporation (TSX: BU), highlighting the company's transition from commissioning into early utilization phase. With the completion of commissioning and launch of commercial production for Peazazz pea protein, Puratein C canola protein, and FavaPro fava protein in fiscal year 2026, Burcon is now focused on ramping up output and customer volume at its Galesburg facility.
In the fourth quarter of fiscal 2026, Burcon reported revenue of $0.83 million, a sequential increase from $0.74 million in the third quarter. Management indicated that current-quarter sales are tracking toward approximately 50% sequential growth based on activity in April and May. The company also set a new production record, with daily output roughly 60% above the levels seen from January to March. As volume builds, the margin opportunity is expected to come from better utilization, a steadier production cadence, and the removal of start-up costs from the run-rate cost structure, rather than relying solely on pricing improvements.
Customer traction is broadening, with more than 30 purchasing customers and over 200 active projects across pea, canola, and fava protein applications. This growing customer base supports the company's ramp-up strategy and positions it for increased revenue. Funding for the Galesburg scale-up is in place, with $6.9 million completed, $3.0 million undrawn, and management targeting $10 million in calendar year 2026 sales.
For more details, see the full announcement here. Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies.
